What is juli?
Juli health operates at the intersection of behavioral science and artificial intelligence, providing a sophisticated platform designed to personalize health tracking and actionable recommendations. By focusing on the granular identification of health triggers, the company enables patients to implement incremental behavioral changes that lead to measurable improvements in long-term health outcomes. The platform is specifically engineered to enhance user retention and engagement, addressing the persistent challenges of adherence in chronic disease management.
In a market increasingly crowded with generic wellness applications, juli health distinguishes itself through a rigorous commitment to clinical validation. Its business model is built upon the premise that data-driven insights, when paired with patient-centric design, can significantly reduce the burden of chronic illness on both the individual and the broader healthcare system.
How much funding has juli raised?
juli has raised a total of $3.8M across 1 funding round:
Angel/Seed
$3.8M
Angel/Seed (2022): $3.8M with participation from DvH Ventures, Speedinvest, Norrsken, and SoftBank Group
Key Investors in juli
DvH Ventures
Dieter von Holtzbrinck Ventures is a venture capital firm that invests early in passionate founders across Europe, providing hands-on support and media-for-equity programs.
Speedinvest
Speedinvest is a venture capital fund with over 1B Euro allocated for investing in pre-Seed, Seed, and early-stage tech startups across Europe, focusing on sectors including Health Bio.
SoftBank Group
SoftBank Group Corp. is a global technology holding company that leverages its investment platforms to back businesses with the potential to shape the next phase of the Information Revolution.
What's next for juli?
With the recent infusion of capital, juli health is well-positioned to scale its enterprise-level offerings and expand its reach within the digital health ecosystem. The strategic focus will likely shift toward deepening its integration with existing healthcare providers and payers, aiming to prove the economic value of its platform in reducing hospital readmissions and improving patient quality of life.
As the company matures, the emphasis will remain on refining its AI algorithms to provide even more precise, real-time interventions. By maintaining its focus on clinical rigor and user-centric design, juli health is poised to capture a larger share of the digital therapeutics market, potentially setting a new standard for how chronic conditions are managed in a post-pandemic, tech-enabled healthcare environment.
